These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 28033332)

  • 1. Comparative Effects of Direct Renin Inhibitor and Angiotensin Receptor Blocker on Albuminuria in Hypertensive Patients with Type 2 Diabetes. A Randomized Controlled Trial.
    Uzu T; Araki SI; Kashiwagi A; Haneda M; Koya D; Yokoyama H; Kida Y; Ikebuchi M; Nakamura T; Nishimura M; Takahara N; Obata T; Omichi N; Sakamoto K; Shingu R; Taki H; Nagai Y; Tokuda H; Kitada M; Misawa M; Nishiyama A; Kobori H; Maegawa H;
    PLoS One; 2016; 11(12):e0164936. PubMed ID: 28033332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of aliskiren on blood pressure and humoral factors in hypertensive hemodialysis patients previously on angiotensin II receptor antagonists.
    Ito T; Ishikawa E; Fujimoto N; Okubo S; Ito G; Ichikawa T; Nomura S; Ito M
    Clin Exp Hypertens; 2014; 36(7):497-502. PubMed ID: 24433061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria.
    Abe M; Maruyama N; Suzuki H; Fujii Y; Ito M; Yoshida Y; Okada K; Soma M
    Hypertens Res; 2012 Aug; 35(8):874-81. PubMed ID: 22592665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Persson F; Desai AS; Nicolaides M; Richard A; Xiang Z; Brunel P; Pfeffer MA;
    N Engl J Med; 2012 Dec; 367(23):2204-13. PubMed ID: 23121378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease.
    Abe M; Suzuki H; Okada K; Maruyama N; Inoshita A; Baba S; Takashima H; Soma M
    Heart Vessels; 2013 Jul; 28(4):442-52. PubMed ID: 22618635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on role of direct renin inhibitor in diabetic kidney disease.
    Dhakarwal P; Agrawal V; Kumar A; Goli KM; Agrawal V
    Ren Fail; 2014 Jul; 36(6):963-9. PubMed ID: 24678880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aliskiren reduces morning blood pressure in hypertensive patients with diabetic nephropathy on hemodialysis.
    Takenaka T; Okayama M; Kojima E; Nodaira Y; Arai J; Uchida K; Kikuta T; Sueyoshi K; Hoshi H; Watanabe Y; Takane H; Suzuki H
    Clin Exp Hypertens; 2013; 35(4):244-9. PubMed ID: 23534458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of direct renin inhibitor, aliskiren, on peripheral blood monocyte subsets and myocardial salvage in patients with primary acute myocardial infarction.
    Ozaki Y; Imanishi T; Tanimoto T; Kashiwagi M; Tsujioka H; Sougawa H; Orii M; Shiono Y; Shimamura K; Ishibashi K; Komukai K; Ino Y; Kitabata H; Akasaka T
    Circ J; 2012; 76(6):1461-8. PubMed ID: 22453004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aliskiren combined with losartan in type 2 diabetes and nephropathy.
    Parving HH; Persson F; Lewis JB; Lewis EJ; Hollenberg NK;
    N Engl J Med; 2008 Jun; 358(23):2433-46. PubMed ID: 18525041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Direct Renin Blockade on Renal & Systemic Hemodynamics and on RAAS Activity, in Weight Excess and Hypertension: A Randomized Clinical Trial.
    Kwakernaak AJ; Roksnoer LC; Lambers Heerspink HJ; van den Berg-Garrelds I; Lochorn GA; van Embden Andres JH; Klijn MA; Kobori H; Danser AH; Laverman GD; Navis GJ
    PLoS One; 2017; 12(1):e0169258. PubMed ID: 28118402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aliskiren and valsartan combination therapy for the management of hypertension.
    Epstein BJ
    Vasc Health Risk Manag; 2010 Sep; 6():711-22. PubMed ID: 20859542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of direct renin inhibitor and angiotensin II receptor blocker on clinic and ambulatory blood pressure profiles in hypertension with chronic kidney disease.
    Uneda K; Tamura K; Wakui H; Azushima K; Haku S; Kobayashi R; Ohki K; Haruhara K; Kinguchi S; Ohsawa M; Fujikawa T; Umemura S
    Clin Exp Hypertens; 2016; 38(8):738-743. PubMed ID: 27936941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin D receptor activation with calcitriol for reducing urinary angiotensinogen in patients with type 2 diabetic chronic kidney disease.
    Tiryaki Ö; Usalan C; Sayiner ZA
    Ren Fail; 2016; 38(2):222-7. PubMed ID: 26707134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?
    de la Sierra A; Salazar J
    Adv Ther; 2011 Sep; 28(9):716-27. PubMed ID: 21809181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?
    Tylicki L; Lizakowski S; Rutkowski P; Renke M; Sulikowska B; Heleniak Z; Donderski R; Bednarski R; Przybylska M; Manitius J; Rutkowski B
    Kidney Blood Press Res; 2012; 36(1):335-43. PubMed ID: 23235363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist.
    Sato A; Fukuda S
    Hypertens Res; 2013 Oct; 36(10):879-84. PubMed ID: 23864056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertension.
    Zhenfeng Zheng ; Huilan Shi ; Junya Jia ; Dong Li ; Shan Lin
    J Renin Angiotensin Aldosterone Syst; 2011 Jun; 12(2):102-12. PubMed ID: 21059822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.